A phase 2 study demonstrated that the objective response rate of talazoparib was seen in 29.8% (31 of 104) of patients, whereas serious treatment-related adverse events were reported in 43 (34%) patients.27 In addition, PARP1/2 selective inhibitors, including niraparib and pamiparib, are currently being tested in phase 2/3 trials of PCa (Table 5). Here, PARP1 is linked to posterior cortical atrophy.